BTIG Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
Analyst Rating on Zimmer Biomet Holdings: Ryan Zimmerman from BTIG has maintained a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $122.00, while the stock currently trades at $104.00. The analyst consensus for ZBH is Hold, with a price target consensus of $121.79.
Market Insights and Performance: Zimmer Biomet Holdings has a market cap of $21.55 billion and a P/E ratio of 20.62. Zimmerman, a 3-star analyst, has an average return of 1.0% and a success rate of 47.85%, focusing on the Healthcare sector.
Trade with 70% Backtested Accuracy
Analyst Views on ZBH
About ZBH
About the author
ZIMMER BIOMET HOLDINGS, INC: BTIG Downgrades Rating to Neutral from Buy
Company Overview: ZIMMER BIOMET HOLDINGS, INC. is a company involved in the medical technology sector, focusing on innovative solutions for musculoskeletal health.
Recent Developments: The company has announced significant cuts to its workforce, indicating a strategic shift or response to market conditions.
Financial Impact: These cuts are expected to have a substantial impact on the company's financial performance and operational efficiency.
Market Position: The changes may affect ZIMMER BIOMET's competitive position in the industry, as it navigates challenges and seeks to optimize its resources.
Schwarzenegger to Speak at AAOS Annual Meeting
- Innovation Showcase: Zimmer Biomet will unveil its latest clinical and operational data at the 2026 AAOS Annual Meeting, emphasizing its leadership in orthopedic implants and robotic technologies, which is expected to attract significant attention from industry professionals.
- Keynote Speaker: Chief Movement Officer Arnold Schwarzenegger will serve as the Presidential Guest Speaker, engaging in discussions with the company's CEO and AAOS President about sustaining peak performance under pressure, thereby enhancing the brand's image.
- Technology Highlights: The exhibit will feature innovations such as the ROSA®Knee and TMINI® systems, aimed at improving surgical precision and patient outcomes through personalized surgical planning and accurate implant placement, further solidifying market competitiveness.
- Data Presentation: New safety and efficacy data for the Oxford® Cementless Partial Knee will be presented, along with efficiency metrics from new processes in ambulatory surgery centers, which are expected to positively influence industry standards.
Zimmer Biomet Announces Q1 2026 Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q1 2026, payable on or about April 30, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for March 31, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term holding among investors.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, committed to enhancing patient experiences through innovative products and digital technologies, showcasing strong market competitiveness.
- Global Business Presence: The company operates in over 25 countries and sells products in more than 100 countries, reflecting the success of its globalization strategy aimed at meeting global health demands through continuous innovation.
Zimmer Biomet Declares Quarterly Dividend of $0.24
- Quarterly Dividend Announcement: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous payouts, indicating the company's ongoing ability to maintain stable cash flow, which is likely to bolster investor confidence.
- Dividend Payment Timeline: The dividend is payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, providing shareholders with a clear timeline that may attract more investors.
- Consecutive Dividend Record: The company has now announced a $0.24 dividend for seventeen consecutive quarters, reflecting its commitment to shareholder returns, which could enhance its attractiveness in the medical device sector.
- Future Outlook: Zimmer Biomet projects revenue growth of 1% to 3% for 2026 amid a U.S. sales force overhaul and innovation cycle, demonstrating management's confidence in future growth, which may influence shareholders' long-term investment perspectives.
ZBH Stock Plummets 15% Amid Revenue Guidance Scrutiny
- Stock Price Drop: Zimmer Biomet Holdings, Inc. (ZBH) experienced a 15% stock decline on November 5, 2025, due to significant revenue misses in Latin America, resulting in a substantial loss of market value and investor confidence.
- Management Confidence Questioned: Despite senior management's claims of “very high” confidence in second-half growth in August 2025, subsequent order cancellations and revenue declines have raised concerns about whether management misled investors, potentially violating federal securities laws.
- Investigation Launched: Hagens Berman law firm is investigating whether ZBH issued overly optimistic financial guidance while concealing operational disruptions, urging affected investors to submit claims for their losses.
- Potential Legal Consequences: Should the investigation reveal misleading statements by ZBH, the company may face legal liabilities, further impacting its market reputation and shareholder trust.
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
ZIMMER BIOMET HOLDINGS, INC: BTIG Downgrades Rating to Neutral from Buy
Company Overview: ZIMMER BIOMET HOLDINGS, INC. is a company involved in the medical technology sector, focusing on innovative solutions for musculoskeletal health.
Recent Developments: The company has announced significant cuts to its workforce, indicating a strategic shift or response to market conditions.
Financial Impact: These cuts are expected to have a substantial impact on the company's financial performance and operational efficiency.
Market Position: The changes may affect ZIMMER BIOMET's competitive position in the industry, as it navigates challenges and seeks to optimize its resources.
Schwarzenegger to Speak at AAOS Annual Meeting
- Innovation Showcase: Zimmer Biomet will unveil its latest clinical and operational data at the 2026 AAOS Annual Meeting, emphasizing its leadership in orthopedic implants and robotic technologies, which is expected to attract significant attention from industry professionals.
- Keynote Speaker: Chief Movement Officer Arnold Schwarzenegger will serve as the Presidential Guest Speaker, engaging in discussions with the company's CEO and AAOS President about sustaining peak performance under pressure, thereby enhancing the brand's image.
- Technology Highlights: The exhibit will feature innovations such as the ROSA®Knee and TMINI® systems, aimed at improving surgical precision and patient outcomes through personalized surgical planning and accurate implant placement, further solidifying market competitiveness.
- Data Presentation: New safety and efficacy data for the Oxford® Cementless Partial Knee will be presented, along with efficiency metrics from new processes in ambulatory surgery centers, which are expected to positively influence industry standards.
Zimmer Biomet Announces Q1 2026 Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q1 2026, payable on or about April 30, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for March 31, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term holding among investors.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, committed to enhancing patient experiences through innovative products and digital technologies, showcasing strong market competitiveness.
- Global Business Presence: The company operates in over 25 countries and sells products in more than 100 countries, reflecting the success of its globalization strategy aimed at meeting global health demands through continuous innovation.
Zimmer Biomet Declares Quarterly Dividend of $0.24
- Quarterly Dividend Announcement: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous payouts, indicating the company's ongoing ability to maintain stable cash flow, which is likely to bolster investor confidence.
- Dividend Payment Timeline: The dividend is payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, providing shareholders with a clear timeline that may attract more investors.
- Consecutive Dividend Record: The company has now announced a $0.24 dividend for seventeen consecutive quarters, reflecting its commitment to shareholder returns, which could enhance its attractiveness in the medical device sector.
- Future Outlook: Zimmer Biomet projects revenue growth of 1% to 3% for 2026 amid a U.S. sales force overhaul and innovation cycle, demonstrating management's confidence in future growth, which may influence shareholders' long-term investment perspectives.
ZBH Stock Plummets 15% Amid Revenue Guidance Scrutiny
- Stock Price Drop: Zimmer Biomet Holdings, Inc. (ZBH) experienced a 15% stock decline on November 5, 2025, due to significant revenue misses in Latin America, resulting in a substantial loss of market value and investor confidence.
- Management Confidence Questioned: Despite senior management's claims of “very high” confidence in second-half growth in August 2025, subsequent order cancellations and revenue declines have raised concerns about whether management misled investors, potentially violating federal securities laws.
- Investigation Launched: Hagens Berman law firm is investigating whether ZBH issued overly optimistic financial guidance while concealing operational disruptions, urging affected investors to submit claims for their losses.
- Potential Legal Consequences: Should the investigation reveal misleading statements by ZBH, the company may face legal liabilities, further impacting its market reputation and shareholder trust.
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
